234 related articles for article (PubMed ID: 10934603)
21. Treatment of bone diseases with bisphosphonates, excluding osteoporosis.
Devogelaer JP
Curr Opin Rheumatol; 2000 Jul; 12(4):331-5. PubMed ID: 10910187
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological therapy of Paget's and other metabolic bone diseases.
Hosking D
Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
[TBL] [Abstract][Full Text] [Related]
23. The therapeutic use of bisphosphonates.
Compston JE
BMJ; 1994 Sep; 309(6956):711-5. PubMed ID: 7950525
[No Abstract] [Full Text] [Related]
24. The mineralization of bone tissue: a forgotten dimension in osteoporosis research.
Boivin G; Meunier PJ
Osteoporos Int; 2003; 14 Suppl 3():S19-24. PubMed ID: 12730799
[TBL] [Abstract][Full Text] [Related]
25. Diphosphonates. Experimental and clinical aspects.
Russell RG; Smith R
J Bone Joint Surg Br; 1973 Feb; 55(1):66-86. PubMed ID: 4632759
[No Abstract] [Full Text] [Related]
26. Clinical value of bisphosphonates in cancer therapy.
Lüftner D; Henschke P; Possinger K
Anticancer Res; 2007; 27(4A):1759-68. PubMed ID: 17649770
[TBL] [Abstract][Full Text] [Related]
27. Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
Shakespeare WC; Metcalf CA; Wang Y; Sundaramoorthi R; Keenan T; Weigele M; Bohacek RS; Dalgarno DC; Sawyer TK
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):729-41. PubMed ID: 14579523
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonates: from bench to bedside.
Russell RG
Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
[TBL] [Abstract][Full Text] [Related]
29. Bisphosphonate treatment of pediatric bone disease.
Speiser PW; Clarson CL; Eugster EA; Kemp SF; Radovick S; Rogol AD; Wilson TA;
Pediatr Endocrinol Rev; 2005 Dec; 3(2):87-96. PubMed ID: 16361982
[TBL] [Abstract][Full Text] [Related]
30. [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
Miki T; Minamide T
Clin Calcium; 2007 Jan; 17(1):18-22. PubMed ID: 17211089
[TBL] [Abstract][Full Text] [Related]
31. Emerging issues with bisphosphonates.
Reid IR
Rheum Dis Clin North Am; 2006 Nov; 32(4):691-702, vi. PubMed ID: 17288972
[TBL] [Abstract][Full Text] [Related]
32. Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis.
Woo T; Adachi JD
Best Pract Res Clin Rheumatol; 2001 Jul; 15(3):469-81. PubMed ID: 11485341
[TBL] [Abstract][Full Text] [Related]
33. [Bisphosphonates and combined treatments osteoporosis].
Rizzoli R; Ferrari S
Rev Med Suisse; 2005 Oct; 1(35):2266, 2269-71. PubMed ID: 16268449
[TBL] [Abstract][Full Text] [Related]
34. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
Brufsky AM
Oncologist; 2008 Feb; 13(2):187-95. PubMed ID: 18305064
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of osteoporosis in octogenarians].
Pepersack T
Rev Med Brux; 2008 Sep; 29(4):311-6. PubMed ID: 18949982
[TBL] [Abstract][Full Text] [Related]
36. [Possibilities of diphosphonates in the therapy of bone diseases].
Bonjour JP; Rizzoli R
Rev Med Suisse Romande; 1990 Aug; 110(8):691-4. PubMed ID: 1699260
[No Abstract] [Full Text] [Related]
37. Bisphosphonates and osteonecrosis of the jaw.
Sambrook P; Olver I; Goss A
Aust Fam Physician; 2006 Oct; 35(10):801-3. PubMed ID: 17019456
[TBL] [Abstract][Full Text] [Related]
38. [Bisphosphonates in the treatment of multiple myeloma].
Stajszczyk M
Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045
[TBL] [Abstract][Full Text] [Related]
39. [Progress in the treatment of osteoporosis].
Sugimoto T
Rinsho Byori; 2008 Oct; 56(10):887-93. PubMed ID: 19068785
[TBL] [Abstract][Full Text] [Related]
40. [Strontium ranelate: a novel concept for the treatment of osteoporosis].
Dimai HP
Wien Klin Wochenschr; 2005 Nov; 117(21-22):728-38. PubMed ID: 16416353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
